VJHemOnc is committed to improving our service to you

ASH 2019 | VenBd in R/R MM: updated analysis of BELLINI

VJHemOnc is committed to improving our service to you

Philippe Moreau

Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France, outlines the updated efficacy and safety results of venetoclax in combination with bortezomib and dexamethasone (VenBd) in relapsed/refractory multiple myeloma (MM) from the BELINNI trial (NCT02755597). Prof. Moreau highlights the favorable benefit of venetoclax, particularly in patients with t(11:14) or high expression of BCL-2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter